Short communication: Survival of replacement kids from birth to mating on commercial dairy goat farms in New Zealand.

Commercial dairy goat systems rely on the successful rearing of kids for herd replacement. The objectives of this study were to (1) determine survival from birth until mating for a large cohort of commercial dairy goat kids; (2) descriptively summarize the causes of mortality and removal from the herd during this period; and (3) compare actual (determined by postmortem examination) and suspected (farmer-reported) causes of mortality. A total of 1,262 female kids were enrolled at birth on 16 commercial dairy goat farms in New Zealand. Median ages at weaning and mating were 86 d [minimum = 54, quartile (Q)1 = 78, Q3 = 97, maximum = 144] and 223 d (minimum = 183, Q1 = 208, Q3 = 237, maximum = 310), respectively. Overall, 87.1% (1,099/1,262) of kids remained on farm at mating, 10.4% (131/1,262) died or were euthanized, and 2.5% (32/1,262) were lost to follow-up or sold. Mortality risk was greatest in early life, with more than 90% of deaths occurring before weaning. Mortality from enrollment to mating varied between farms (minimum = 0%, Q1 = 5.9%, median = 8.9%, Q3 = 15.8%, maximum = 20.5%). The leading cause of death was gastrointestinal disorders (33.6%, 36/107), followed by disbudding-related injury (15.9%, 17/107), and septicemia (12.1%, 13/107). Farmers correctly identified approximately half of the deaths attributed to gastrointestinal disorders (56.0%, 14/25) and disbudding-related injury (44.4%, 4/9), but were less successful at diagnosing septicemia (0%, 0/5), starvation or dehydration (0%, 0/4), and suffocation (18.8% 3/16). This is the largest cohort of dairy goat kids to be systematically followed over time to confirm survival until mating and to determine causes of death by postmortem examination. We found that kid mortality was highest during the preweaning period and there was often a discrepancy between farmer-perceived and actual cause of death. Postmortem examinations should be more widely used to establish causes of death and inform on-farm strategies to reduce kid mortality.

Effects of milk replacer acidification and free-access feeding on early life feeding, oral, and lying behavior of dairy calves.

Acidification is a practical way of preserving the bacteriological quality of milk so that it can be fed to calves under free-access conditions. The objectives of this study were to evaluate how milk replacer acidification and free-access feeding affect dairy calf behavior during the first week of life. Sixteen Holstein male calves were purchased at birth and transported to the University of Guelph Kemptville Campus Dairy Education and Research Centre. Calves were randomly assigned to 1 of 4 milk feeding programs: (1) free-access (ad libitum) feeding of acidified milk replacer (22% crude protein and 17% fat, 150 g/L; FA); (2) restricted (6 L/d, 150 g/L) feeding of acidified milk replacer (RA); (3) free-access feeding of nonacidified milk replacer (FN); and (4) restricted feeding of nonacidified milk replacer (RN). Formic acid was used to acidify milk replacer to a target pH between 4.0 and 4.5. Video recordings of each calf at 1, 2, and 6 d were analyzed continuously over 24 h for all occurrences of each behavior in the ethogram. Feeding behavior observations were organized into sucking bouts, from which feeding behavior outcome variables were calculated. Calves consuming acidified milk replacer demonstrated more fragmented feeding patterns, characterized by more pauses within a sucking bout (FA, FN, RA, and RN calves = 12.4, 4.4, 13.7, and 11.9 pauses/bout, respectively) and longer sucking bout duration (FA, FN, RA, and RN calves = 8.8, 5.2, 9.3, and 8.1 min/bout, respectively), than calves fed nonacidified milk replacer. Restricted-fed calves tended to have longer sucking bouts and performed more within-bout sucks (FA, FN, RA, and RN calves = 10.7, 5.8, 13.5, and 14.1, respectively) and pauses than free-access calves. Acidification and free-access feeding did not affect lying duration. Calves assigned to the acidified feeding treatments tended to perform more grooming behavior than those fed nonacidified milk replacer (FA, FN, RA, and RN calves = 0.9, 0.5, 0.8, and 0.6 h/d, respectively). Free-access feeding did not affect grooming duration. The observed differences in feeding and grooming behavior suggest that acidification to a pH between 4.0 and 4.5 may have altered the palatability of milk replacer. Calves assigned to the acidified milk replacer feeding treatments did not, however, show avoidance toward this feedstuff during the first week of life.

Clinical trial on the effects of a free-access acidified milk replacer feeding program on the health and growth of dairy replacement heifers and veal calves.

The objectives of this study were to evaluate the effects of free-access acidified milk replacer feeding on the pre- and postweaning health of dairy and veal calves. Individually housed calves were systematically assigned at birth to 1 of 2 feeding programs: free-access feeding (ad libitum) of acidified milk replacer (ACD, n=249) or traditional restricted feeding (3L fed twice daily) of milk replacer (RES, n=249). Calves were fed milk replacer containing 24% crude protein and 18% fat. Acidified milk replacer was prepared to a target pH between 4.0 and 4.5 using formic acid. Calves were weaned off milk replacer at approximately 6wk of age. Weaning occurred over 5d, and during this weaning period, ACD calves had access to milk replacer for 12h/d and RES calves were offered only one feeding of milk replacer (3 L) daily. Calves were monitored daily for signs of disease. Fecal consistency scores were assigned each week from birth until weaning. A subset of calves was systematically selected for fecal sampling at 3 time points between 7 and 27d of age. Fecal samples were analyzed for enterotoxigenic Escherichia coli F5, Cryptosporidium parvum, rotavirus, and coronavirus. Hip width, hip height, body length, heart girth, and body weight were measured at birth and weaning. Postweaning body weight measurements were collected from the heifers at approximately 8mo of age. Postweaning body weight and carcass grading information was collected from the veal calves at slaughter once a live weight between 300 and 350kg had been achieved. The odds of ACD calves being treated for a preweaning disease event tended to be lower than that of the RES calves (1.2 vs. 5.2%, respectively). Preweaning mortality, postweaning disease treatment, and postweaning mortality did not differ between feeding treatments. The ACD feeding treatment supported greater preweaning average daily gain (0.59 vs. 0.43kg/d) and structural growth than RES feeding. Postweaning average daily gain and carcass characteristics were similar for ACD and RES calves. These results indicate that free-access acidified milk replacer feeding tended to support improved health, and greater body weight gain and structural growth during the preweaning period; these effects did not persist in the postweaning period. The growth advantage observed before weaning in the ACD calves likely disappeared due to the weaning methods used.

An observational study on passive immunity in Irish suckler beef and dairy calves: Tests for failure of passive transfer of immunity and associations with health and performance.

The study objectives were to: 1) evaluate the diagnostic performance of passive immunity tests for classification of failure of passive transfer (FPT) risk, based on their relationships with calf health and performance, and 2) describe the epidemiology of morbidity and mortality in suckler beef and dairy calves under Irish conditions. A total of 1392 suckler beef calves (n = 111 farms) and 2090 dairy calves (84 farms) were included in this observational study. Blood samples were collected by jugular venipuncture. Serum samples were analysed for total IgG concentration using an ELISA assay, total protein concentration by clinical analyser (TP - CA), globulin concentration, zinc sulphate turbidity (ZST) units, total solids percentage by Brix refractometer (TS - BRIX), and total protein concentration by digital refractometer (TP - DR). Crude and cause-specific morbidity, all-cause mortality, and standardised 205-day body weight (BW) were determined. Generalised linear mixed models were used to evaluate associations between suckler beef and dairy calves for morbidity, mortality, growth and passive immunity. Receiver operating characteristic (ROC) curves were constructed to determine optimal test cut-offs for classification of health and growth outcomes. Overall, 20% of suckler beef and 30% of dairy calves were treated for at least one disease event by 6 mo. of age. Suckler beef calves had greater odds of bovine respiratory disease (BRD; odds ratio (OR), 95% confidence interval (CI): 2.8, 1.2-6.5, P = 0.01), navel infection (5.1, 1.9-13.2, P < 0.001), and joint infection/lameness (3.2, 1.3-7.8, P = 0.01) during the first 6 mo. of life than dairy calves. In addition, from birth to 6 mo. of age, suckler beef calves had greater rates of navel infection (incidence rate ratio (IRR), 95% CI: 3.3, 1.3-8.4, P = 0.01), but decreased rates of diarrhoea (0.9, 0.2-0.9, P = 0.03) compared to dairy calves. Optimal test cut-offs for classification of morbidity and mortality outcomes in suckler beef calves ranged from 8 to 9 mg/ml ELISA, 56 to 61 g/l TP - CA, 26 to 40 g/l globulin, 12 to 18 ZST units, 8.4% TS - BRIX, and 5.3 to 6.3 g/dl TP - DR. Optimal test cut-offs for classification of morbidity and growth outcomes in dairy calves ranged from 10 to 12 mg/ml ELISA, 57 to 60 g/l TP - CA, 29 to 34 g/l globulin, 19 ZST units, 7.8 to 8.4% TS - BRIX, and 5.7 to 5.9 g/dl TP - DR.

Nonsteroidal anti-inflammatory drug therapy for neonatal calf diarrhea complex: Effects on calf performance.

The aim of this study was to examine the efficacy of meloxicam (MEL) as supportive therapy for calves with neonatal calf diarrhea complex. For this double-blind controlled trial, 62 Holstein male calves were purchased at birth and transported to a research facility. At the naturally occurring onset of diarrhea, defined as the first occurrence of a fecal score greater than 2 on a 4-point scale, calves were enrolled in the study. Each calf with diarrhea was randomly assigned to receive a single subcutaneous injection of MEL at a rate of 0.5 mg/kg of BW or an equal volume of placebo (PLA) solution. Milk, starter ration, and water intakes were determined daily for each calf from arrival until 56 d of age. The calves were weighed on arrival and each week thereafter. Time to weaning and weaning weight were recorded for each calf. Crude associations between treatment and each outcome variable were examined using t-tests and Pearson chi-squared tests. Subsequently, multivariable regression models were constructed to examine the impact of MEL therapy on meaningful outcome variables. The primary experimental unit in all analyses was the individual calf. In total, 56 calves presented with clinical signs of diarrhea and were enrolled in the study. Two PLA-treated calves died after being enrolled in the study, and there was no calf mortality among the MEL-treated calves. For calves that developed diarrhea after 10 d of age, MEL-treated calves were more likely to consume their entire daily milk allowance (P < 0.05) as compared with PLA-treated calves. Meloxicam-treated calves began consuming starter ration earlier (P < 0.01) and at a greater rate (P < 0.001), and consumed more water (P < 0.001) compared with PLA-treated animals. Over the study period, calves treated with MEL gained BW at a faster rate (P < 0.01) than calves treated with PLA. There was no difference in weaning weight (P > 0.05), but MEL-treated calves tended to wean earlier (P = 0.11) than PLA-treated calves. These results demonstrate that calves receiving a single injection of MEL at the onset of diarrhea had improved appetite and performance compared with PLA-treated calves. Thus, MEL is an effective supportive therapy for neonatal calf diarrhea complex.

Effect of halofuginone lactate on the occurrence of Cryptosporidium parvum and growth of neonatal dairy calves.

Thirty-one Holstein bull calves were purchased at birth from 3 dairy farms in Eastern Ontario. Each calf was assigned at random to oral treatment with either 5 mg of halofuginone lactate in 10.0 mL of aqueous carrier solution (Halocur, base comprised 10 mg of benzoic acid, 100 mg of lactic acid, and 0.3 mg of tartrazine) or 10 mL of placebo (Halocur base minus the active ingredient, halofuginone lactate) administered 15 to 30 min after morning milk feeding for the first 7 d of life. Intakes of milk, calf starter, and water, and fecal consistency score were recorded daily for 56 d. Calf weights were recorded weekly for 56 d. Fecal samples were taken from all calves at approximately 2, 7, 14, 21, and 28 d of age for isolation of Cryptosporidium parvum oocysts. Logistic and linear regression analyses were used to assess the effect of treatment on the incidence of diarrhea and C. parvum infection status. The odds of C. parvum shedding among calves in the halofuginone lactate-treated group was 70% lower than the odds of shedding among calves in the placebo group. In calves treated with halofuginone lactate, no oocyst shedding occurred until 2 wk of age, whereas 12.5% of calves in the placebo group began shedding oocysts during wk 1. From all ages of placebo-treated calves, 31 of 73 samples (42.5%) were positive for C. parvum, whereas only 15 of 67 samples (22.4%) from all ages of halofuginone lactate-treated calves tested positive. The largest number of C. parvum-positive samples occurred in the third week of life. There was a significant delay of 3.1 d in the incidence of diarrhea among calves treated with halofuginone lactate. Intake of milk and starter, body weight gains, and age at weaning were not significantly different between treatment groups.